Davita Inc (NYSE:DVA)‘s stock had its “sell” rating reiterated by equities researchers at Goldman Sachs Group Inc in a research note issued on Thursday. They presently have a $62.00 target price on the stock. Goldman Sachs Group Inc’s price target points to a potential downside of 6.44% from the stock’s current price.

A number of other equities research analysts have also recently issued reports on DVA. TheStreet upgraded Davita from a “c+” rating to a “b-” rating in a research note on Monday, April 3rd. Zacks Investment Research upgraded Davita from a “hold” rating to a “buy” rating and set a $77.00 target price on the stock in a research note on Tuesday, April 18th. Finally, Royal Bank of Canada reiterated a “hold” rating and issued a $62.00 target price on shares of Davita in a research note on Friday, February 17th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and three have issued a buy rating to the company’s stock. Davita presently has an average rating of “Hold” and a consensus target price of $69.50.

Analyst Recommendations for Davita (NYSE:DVA)

Shares of Davita (NYSE:DVA) traded up 2.32% during trading on Thursday, reaching $66.27. 2,150,649 shares of the company’s stock were exchanged. The stock has a market capitalization of $12.90 billion, a PE ratio of 10.88 and a beta of 1.02. Davita has a 52 week low of $54.50 and a 52 week high of $78.77. The company’s 50-day moving average is $66.87 and its 200 day moving average is $65.58.

Davita (NYSE:DVA) last released its quarterly earnings data on Tuesday, May 2nd. The company reported $0.79 EPS for the quarter, missing analysts’ consensus estimates of $0.82 by $0.03. The business had revenue of $3.70 billion during the quarter, compared to analyst estimates of $3.69 billion. Davita had a return on equity of 16.16% and a net margin of 4.92%. On average, analysts forecast that Davita will post $3.55 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Davita Inc (DVA) Given Sell Rating at Goldman Sachs Group Inc” was first published by American Banking News and is owned by of American Banking News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/05/25/davita-inc-dva-given-sell-rating-at-goldman-sachs-group-inc.html.

In related news, CEO Javier Rodriguez sold 1,294 shares of Davita stock in a transaction dated Monday, May 15th. The shares were sold at an average price of $66.21, for a total transaction of $85,675.74. Following the sale, the chief executive officer now directly owns 99,111 shares in the company, valued at $6,562,139.31. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Charles Berg sold 8,414 shares of Davita stock in a transaction dated Tuesday, May 9th. The shares were sold at an average price of $65.80, for a total transaction of $553,641.20. Following the sale, the director now owns 34,719 shares in the company, valued at $2,284,510.20. The disclosure for this sale can be found here. Insiders sold 22,702 shares of company stock worth $1,495,492 over the last quarter. 2.10% of the stock is currently owned by company insiders.

Several large investors have recently modified their holdings of DVA. Advantus Capital Management Inc boosted its stake in shares of Davita by 2.4% in the third quarter. Advantus Capital Management Inc now owns 16,406 shares of the company’s stock worth $1,084,000 after buying an additional 388 shares in the last quarter. Green Square Capital LLC bought a new stake in shares of Davita during the third quarter worth $264,000. Peloton Wealth Strategists bought a new stake in shares of Davita during the third quarter worth $1,302,000. Accident Compensation Corp bought a new stake in shares of Davita during the third quarter worth $529,000. Finally, Russell Investments Group Ltd. bought a new stake in shares of Davita during the fourth quarter worth $8,737,000. Institutional investors and hedge funds own 85.31% of the company’s stock.

About Davita

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

12 Month Chart for NYSE:DVA

Receive News & Ratings for Davita Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Davita Inc and related companies with MarketBeat.com's FREE daily email newsletter.